跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 30,184 条关于
“primary mediastinal LBCL”
全部
30,184
临床试验
19,071
药物
133
机构
33
资讯
10,947
去年
Glofitamab Plus Polatuzumab Demonstrates Durable Responses in Relapsed/Refractory LBCL
去年
SBRT Followed by Chemoradiotherapy Shows Promise in Locally Advanced NSCLC
3年前
Anbalcabtagene Autoleucel Shows 84% Response Rate in Relapsed/Refractory Large B-Cell Lymphoma
去年
Lisocabtagene Maraleucel Shows Promise in Relapsed/Refractory Lymphomas
3年前
Axicabtagene Ciloleucel Approved for Second-Line LBCL Treatment
去年
Real-World Data Confirm Axi-Cel Efficacy in Second-Line LBCL
2年前
Axicabtagene Ciloleucel Shows Promise in Second-Line LBCL for Transplant-Ineligible Patients
去年
Epcoritamab Demonstrates Durable 3-Year Remissions in Relapsed/Refractory Large B-Cell Lymphoma
去年
CARGO Therapeutics Discontinues Phase 2 Firi-Cel Trial in R/R LBCL Due to Safety, Durability Concerns
去年
FDA Grants RMAT Designation to Lyell's Dual-Targeting CAR T-Cell Therapy LYL314 for Relapsed/Refractory LBCL
第 1 页,共 1095 页
上一页
下一页